SELLAS Life Sciences Group, Inc. (SLS)
11.74
+0.41
(+3.62%)
USD |
NASDAQ |
Oct 02, 16:00
11.75
+0.01
(+0.09%)
After-Hours: 20:00
SELLAS Life Sciences Group EPS Diluted (Quarterly) : -0.0508 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0508 |
| March 31, 2026 | -0.0487 |
| December 31, 2025 | -0.05 |
| September 30, 2025 | -0.0626 |
| June 30, 2025 | -0.067 |
| March 31, 2025 | -0.0662 |
| December 31, 2024 | -0.0911 |
| September 30, 2024 | -0.1041 |
| June 30, 2024 | -0.1296 |
| March 31, 2024 | -0.2135 |
| December 31, 2023 | -0.2533 |
| September 30, 2023 | -0.3268 |
| June 30, 2023 | -0.3118 |
| March 31, 2023 | -0.4713 |
| December 31, 2022 | -0.4342 |
| September 30, 2022 | -0.3415 |
| June 30, 2022 | -0.4148 |
| March 31, 2022 | -1.053 |
| December 31, 2021 | -0.4151 |
| September 30, 2021 | -0.4463 |
| June 30, 2021 | -0.3021 |
| March 31, 2021 | -0.1615 |
| December 31, 2020 | -0.282 |
| September 30, 2020 | -0.5314 |
| June 30, 2020 | -0.6587 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.6499 |
| December 31, 2019 | -1.460 |
| September 30, 2019 | -2.678 |
| June 30, 2019 | -6.326 |
| March 31, 2019 | -11.12 |
| December 31, 2018 | -30.24 |
| September 30, 2018 | -26.75 |
| June 30, 2018 | -63.00 |
| March 31, 2018 | -83.50 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | -3404.52 |
| June 30, 2017 | -6749.97 |
| March 31, 2017 | -5444.97 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | -900.09 |
| June 30, 2016 | 900.09 |
| March 31, 2016 | -2700.27 |
| December 31, 2015 | -2803.48 |
| September 30, 2015 | -3300.33 |
| June 30, 2015 | -3000.30 |
| March 31, 2015 | -2400.24 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | -1500.15 |
| June 30, 2014 | -5100.51 |
| March 31, 2014 | -600.06 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AbbVie, Inc. | 2.033 |
| Capricor Therapeutics, Inc. | -0.7032 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Incyte Corp. | 2.812 |
| Insmed, Inc. | -0.0609 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -9.605M |
| Total Expenses (Quarterly) | 9.605M |
| Enterprise Value | 2.233B |
| Earnings Yield | -1.81% |
| Normalized Earnings Yield | -1.808 |